Alphatec Holdings, Inc.
16.49-0.16 (-0.96%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · ATEC · USD
Key Stats
Market Cap
2.44BP/E (TTM)
-Basic EPS (TTM)
-1.13Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Alphatec Holdings posted solid Q2 FY2025 results, with revenue climbing 27% year-over-year to $185.5M from $145.6M, fueled by surgeon adoption and product expansion, while gross margin held steady at 69.6%. Operating loss narrowed to $13.1M from $35.3M, thanks to controlled expenses, but net loss widened to $41.1M versus $40.7M, driven by higher interest costs and a $16.8M derivative hit on new convertible notes. Cash swelled to $157.1M after issuing $405M in 2030 Notes and repurchasing 80% of 2026 Notes for $268.4M, with free cash flow positive at $10.5M from operations minus $23.8M capex. Debt stands at $552M, including a $200M term loan at 10.19%. Revenue growth persists. Yet tariffs on imports could squeeze margins amid rising international sales.
8-K
Q2 revenue jumps 27.5%
Alphatec Holdings reported Q2 2025 total revenue of $186 million, up 27.5% year-over-year, with surgical revenue surging 29% to $168 million on strong PTP and LTP product momentum. Adjusted EBITDA hit $23 million at 13% margin, expanding 880 basis points, while non-GAAP net income turned positive at $3 million. The company raised full-year guidance to $742 million revenue and $83 million adjusted EBITDA. Momentum builds, yet litigation costs linger.
8-K
Authorized shares doubled
Alphatec Holdings boosted its authorized shares from 220 million to 420 million, with common stock rising to 400 million, effective June 12, 2025, after stockholder approval at the June 11 annual meeting. Stockholders also greenlit a 2016 equity plan amendment, expanding available shares to 38,383,333. This positions the company for flexible capital raises. Yet dilution looms for existing holders.
10-Q
Q1 FY2025 results
Alphatec Holdings kicked off FY2025 with revenue surging 22% year-over-year to $169.2M for the quarter ended March 31, 2025, fueled by broader surgeon adoption and new product launches, while gross profit climbed to $116.0M for a steady 68.6% margin. Operating loss widened slightly to $44.3M amid higher sales, general, and administrative costs up 12% and litigation expenses ballooning 176% from a settlement, yet net loss held near flat at $51.9M or $(0.35) per diluted share on 146.7M shares. Cash swelled to $153.2M after netting $392.9M from issuing $405.0M 0.75% convertible notes due 2030, offset by repurchasing 80% of the 2026 notes for $268.4M and $42.5M in capped calls; total debt stands at $548.4M with $60M revolver availability. Free cash flow improved to $(16.7M) (derived) from operating outflow of $5.0M minus $11.6M capex. Litigation shadows persist.
8-K
Q1 revenue up 22%
Alphatec Holdings reported Q1 2025 revenue of $169 million, up 22% year-over-year, with surgical revenue surging 24% to $152 million on 17% procedural volume growth and 18% new surgeon adoption. Adjusted EBITDA hit $11 million, a 840 bps margin improvement from disciplined cost controls, while free cash use dropped $55 million. The company refinanced convertible debt to 2030 and raised full-year guidance to $734 million revenue and $78 million adjusted EBITDA. Momentum builds, yet litigation expenses persist.
ALC
Alcon Inc.
73.60-1.22
ALRTF
ALR Technologies SG LTD.
0.02+0.00
AVNS
Avanos Medical, Inc.
11.43-0.15
GMED
Globus Medical, Inc.
61.48-1.27
IART
Integra LifeSciences Holdings C
15.43-0.13
OFIX
Orthofix Medical Inc.
15.32-0.70
SIBN
SI-BONE, Inc.
15.26-0.53
TELA
TELA Bio, Inc.
1.32-0.12
TNON
Tenon Medical, Inc.
1.23+0.01
XTNT
Xtant Medical Holdings, Inc.
0.90+0.03